Search results
Revolutionizing Cancer Treatment: Key to Prolonging CAR T Cell Life Uncovered
SciTechDaily· 3 days agoFOXO1 is required for T cell memory and is linked to longer-lasting clinical outcomes in CAR T cell...
Turning a tumor's 'shield' into a weapon against itself
Medical Xpress· 21 hours agoWang, the Chair of the Alfred E. Mann Department of Biomedical Engineering and the Dwight C. and...
New technique improves T cell-based immunotherapies for solid tumors
Medical Xpress· 2 days agoScientists from Scripps Research have enhanced an existing immunotherapy by removing the sugar coating surrounding solid tumors—such as in melanoma, breast, and prostate cancer—so T cells can ...
ImmunityBio partners with Serum Institute for BCG vaccines
Pharmaceutical Technology via Yahoo Finance· 2 hours agoImmunityBio has entered an exclusive worldwide agreement with the Serum Institute of India to secure...
Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach - Leukemia
Nature· 3 days agoChimeric antigen receptor (CAR) T-cells have recently been demonstrated to be highly effective in the disease, but the survival curves are yet to plateau. Thus, on-target, off-tumour toxicity ...
Replay wins IND clearance for PRAME T cell cancer therapy
Pharmaceutical Technology via Yahoo Finance· 2 days agoGenome writing company Replay Bio has had its investigational new drug (IND) application cleared by...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 1 day agoPlanegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of
Researchers reveal how protein modifications power T cells
Newswise· 4 days agoIn our cells, molecules called phosphate groups are constantly attaching to—or detaching...
Biomarkers identified for successful treatment of bone marrow tumors
Medical Xpress· 7 days agoCAR T cell therapy has proven effective in treating various hematological cancers. In a clinical study, researchers from the University of Leipzig Medical ...
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Morningstar· 2 days agoThe extension also has options to extend the collaboration for up to an additional two years. Under the collaboration, Bristol Myers Squibb has opted into 13 different programs...